| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4166685 | The Journal of Pediatrics | 2009 | 4 Pages |
Abstract
To report on the efficacy of rituximab (RTX) therapy in standard treatment–refractory, chronic Henoch-Schönlein purpura, a retrospective chart review of 3 pediatric patients treated with RTX for severe refractory chronic Henoch-Schönlein purpura was performed. All 3 patients responded to 1 or 2 courses of RTX without serious adverse events.
Related Topics
Health Sciences
Medicine and Dentistry
Perinatology, Pediatrics and Child Health
Authors
Katherine J. Donnithorne, T. Prescott Atkinson, Claas H. Hinze, Janaina B. Nogueira, Shehzad A. Saeed, David J. Askenazi, Timothy Beukelman, Randy Q. Cron,